Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anesthesia, Obstetrical | 8 | 2023 | 22 | 2.800 |
Why?
|
| Ghana | 16 | 2022 | 23 | 1.690 |
Why?
|
| Referral and Consultation | 4 | 2022 | 147 | 1.670 |
Why?
|
| Pregnancy | 24 | 2023 | 981 | 1.620 |
Why?
|
| Delivery, Obstetric | 5 | 2017 | 58 | 1.600 |
Why?
|
| Maternal Health Services | 4 | 2018 | 9 | 1.510 |
Why?
|
| Anesthesiology | 3 | 2023 | 48 | 1.440 |
Why?
|
| Analgesia, Obstetrical | 7 | 2015 | 47 | 1.240 |
Why?
|
| Cesarean Section | 7 | 2015 | 113 | 1.130 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 194 | 1.130 |
Why?
|
| Triage | 3 | 2020 | 75 | 1.060 |
Why?
|
| Infant Mortality | 3 | 2020 | 26 | 1.050 |
Why?
|
| Anesthesia, Spinal | 4 | 2015 | 20 | 1.030 |
Why?
|
| Maternal Mortality | 4 | 2017 | 12 | 1.030 |
Why?
|
| International Cooperation | 2 | 2017 | 30 | 1.020 |
Why?
|
| Pregnancy Complications | 3 | 2016 | 111 | 0.940 |
Why?
|
| Anesthetics, Local | 7 | 2009 | 81 | 0.910 |
Why?
|
| Anesthesia, Epidural | 6 | 2014 | 24 | 0.900 |
Why?
|
| Labor, Obstetric | 4 | 2018 | 35 | 0.830 |
Why?
|
| Bupivacaine | 7 | 2009 | 52 | 0.830 |
Why?
|
| Midwifery | 3 | 2020 | 3 | 0.800 |
Why?
|
| Medically Underserved Area | 2 | 2014 | 23 | 0.780 |
Why?
|
| Technology | 1 | 2022 | 11 | 0.740 |
Why?
|
| Amides | 5 | 2004 | 18 | 0.730 |
Why?
|
| Female | 29 | 2023 | 20375 | 0.710 |
Why?
|
| Hospitals, Maternity | 1 | 2020 | 1 | 0.670 |
Why?
|
| Postnatal Care | 1 | 2020 | 5 | 0.670 |
Why?
|
| Humans | 34 | 2023 | 32967 | 0.630 |
Why?
|
| Health Education | 1 | 2020 | 162 | 0.610 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 175 | 0.570 |
Why?
|
| Infant, Newborn | 10 | 2023 | 694 | 0.570 |
Why?
|
| Adult | 19 | 2020 | 9586 | 0.560 |
Why?
|
| Teaching | 3 | 2018 | 61 | 0.540 |
Why?
|
| Analgesia, Epidural | 4 | 2008 | 50 | 0.540 |
Why?
|
| Capacity Building | 2 | 2019 | 4 | 0.530 |
Why?
|
| Program Evaluation | 6 | 2019 | 181 | 0.530 |
Why?
|
| Organizations | 1 | 2016 | 4 | 0.490 |
Why?
|
| Anesthesia, Conduction | 2 | 2008 | 24 | 0.490 |
Why?
|
| Models, Organizational | 1 | 2016 | 15 | 0.490 |
Why?
|
| Tranexamic Acid | 1 | 2015 | 5 | 0.480 |
Why?
|
| Antifibrinolytic Agents | 1 | 2015 | 16 | 0.470 |
Why?
|
| Magnesium Sulfate | 1 | 2015 | 14 | 0.470 |
Why?
|
| Status Epilepticus | 1 | 2015 | 18 | 0.470 |
Why?
|
| Medication Errors | 1 | 2015 | 22 | 0.470 |
Why?
|
| Pregnancy Outcome | 2 | 2015 | 91 | 0.470 |
Why?
|
| Operating Rooms | 1 | 2015 | 43 | 0.440 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 130 | 0.420 |
Why?
|
| Infant | 3 | 2023 | 1083 | 0.420 |
Why?
|
| Decision Making | 1 | 2015 | 203 | 0.390 |
Why?
|
| Fentanyl | 3 | 2002 | 32 | 0.370 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2011 | 17 | 0.350 |
Why?
|
| Analgesics, Opioid | 3 | 2002 | 252 | 0.340 |
Why?
|
| Health Personnel | 3 | 2020 | 131 | 0.320 |
Why?
|
| Dipeptides | 2 | 2000 | 9 | 0.300 |
Why?
|
| Patient Care Team | 1 | 2010 | 123 | 0.290 |
Why?
|
| Hospitals | 3 | 2017 | 109 | 0.290 |
Why?
|
| Neostigmine | 3 | 2009 | 22 | 0.280 |
Why?
|
| Program Development | 3 | 2019 | 96 | 0.280 |
Why?
|
| Hemorrhage | 2 | 2017 | 107 | 0.250 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2009 | 37 | 0.230 |
Why?
|
| Education | 2 | 2018 | 37 | 0.220 |
Why?
|
| Analgesia | 2 | 2004 | 30 | 0.220 |
Why?
|
| Central Nervous System Diseases | 1 | 2004 | 13 | 0.210 |
Why?
|
| Nerve Block | 1 | 2004 | 50 | 0.210 |
Why?
|
| Postural Balance | 1 | 2016 | 180 | 0.210 |
Why?
|
| Pesticides | 1 | 2016 | 196 | 0.200 |
Why?
|
| Occupational Exposure | 1 | 2016 | 231 | 0.200 |
Why?
|
| Time Factors | 3 | 2020 | 2195 | 0.200 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 240 | 0.190 |
Why?
|
| Transients and Migrants | 1 | 2016 | 298 | 0.190 |
Why?
|
| Young Adult | 3 | 2020 | 2738 | 0.180 |
Why?
|
| Resuscitation | 2 | 2014 | 67 | 0.180 |
Why?
|
| Piperidines | 1 | 2002 | 120 | 0.170 |
Why?
|
| Pain Measurement | 5 | 2009 | 356 | 0.170 |
Why?
|
| Feasibility Studies | 1 | 2022 | 308 | 0.170 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 34 | 0.170 |
Why?
|
| Respiration | 1 | 2000 | 30 | 0.170 |
Why?
|
| Health Plan Implementation | 1 | 2020 | 21 | 0.160 |
Why?
|
| Morphine | 1 | 2000 | 47 | 0.160 |
Why?
|
| Counseling | 1 | 2020 | 98 | 0.160 |
Why?
|
| Adjuvants, Anesthesia | 1 | 2000 | 5 | 0.160 |
Why?
|
| Anesthesia, Local | 1 | 2000 | 15 | 0.160 |
Why?
|
| Obstetrics | 1 | 2020 | 28 | 0.160 |
Why?
|
| Hispanic Americans | 1 | 2016 | 930 | 0.160 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2000 | 41 | 0.160 |
Why?
|
| Mothers | 1 | 2020 | 91 | 0.160 |
Why?
|
| Injections, Spinal | 2 | 2015 | 108 | 0.160 |
Why?
|
| Analgesia, Patient-Controlled | 3 | 2009 | 19 | 0.150 |
Why?
|
| Clonidine | 1 | 2000 | 62 | 0.150 |
Why?
|
| Patient Discharge | 1 | 2020 | 205 | 0.150 |
Why?
|
| Clinical Protocols | 2 | 2019 | 91 | 0.150 |
Why?
|
| Leadership | 1 | 2019 | 40 | 0.140 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2018 | 33 | 0.140 |
Why?
|
| Cross Infection | 1 | 2018 | 56 | 0.140 |
Why?
|
| Blood Pressure | 3 | 2009 | 867 | 0.140 |
Why?
|
| Armenia | 1 | 2017 | 1 | 0.130 |
Why?
|
| Fetal Mortality | 1 | 2017 | 1 | 0.130 |
Why?
|
| Monte Carlo Method | 1 | 2017 | 19 | 0.130 |
Why?
|
| Focus Groups | 1 | 2018 | 128 | 0.130 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2017 | 13 | 0.130 |
Why?
|
| Stillbirth | 1 | 2017 | 13 | 0.130 |
Why?
|
| Hypotension | 1 | 1997 | 48 | 0.130 |
Why?
|
| Educational Status | 1 | 2018 | 183 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 360 | 0.130 |
Why?
|
| Prospective Studies | 3 | 2017 | 2338 | 0.120 |
Why?
|
| Risk Adjustment | 1 | 2016 | 26 | 0.120 |
Why?
|
| Male | 7 | 2019 | 19754 | 0.120 |
Why?
|
| Demography | 1 | 2016 | 110 | 0.120 |
Why?
|
| Receptors, GABA-A | 1 | 2015 | 32 | 0.120 |
Why?
|
| Regression Analysis | 1 | 2016 | 288 | 0.120 |
Why?
|
| Emergencies | 1 | 2015 | 45 | 0.110 |
Why?
|
| Developing Countries | 1 | 2015 | 57 | 0.110 |
Why?
|
| Retrospective Studies | 2 | 2017 | 3708 | 0.100 |
Why?
|
| Quality Assurance, Health Care | 1 | 2014 | 72 | 0.100 |
Why?
|
| Monitoring, Physiologic | 1 | 2014 | 77 | 0.100 |
Why?
|
| Curriculum | 1 | 2015 | 211 | 0.100 |
Why?
|
| Middle Aged | 3 | 2018 | 12203 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 265 | 0.090 |
Why?
|
| Regional Health Planning | 1 | 2011 | 9 | 0.090 |
Why?
|
| Education, Nursing | 1 | 2010 | 1 | 0.080 |
Why?
|
| Altruism | 1 | 2010 | 6 | 0.080 |
Why?
|
| Parturition | 1 | 2010 | 11 | 0.080 |
Why?
|
| Injections, Intraventricular | 2 | 2000 | 13 | 0.080 |
Why?
|
| Risk Factors | 1 | 2017 | 4001 | 0.080 |
Why?
|
| Anesthesia | 1 | 2010 | 64 | 0.080 |
Why?
|
| Cooperative Behavior | 1 | 2010 | 84 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2015 | 3460 | 0.070 |
Why?
|
| Critical Care | 1 | 2010 | 109 | 0.070 |
Why?
|
| Croatia | 1 | 2008 | 1 | 0.070 |
Why?
|
| Organizations, Nonprofit | 1 | 2008 | 6 | 0.070 |
Why?
|
| Adolescent | 1 | 2015 | 3643 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2000 | 754 | 0.060 |
Why?
|
| Needles | 1 | 2005 | 31 | 0.060 |
Why?
|
| Rats | 2 | 2000 | 1610 | 0.060 |
Why?
|
| Total Quality Management | 1 | 2004 | 17 | 0.050 |
Why?
|
| Anesthesia, General | 1 | 2004 | 33 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2004 | 156 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2016 | 880 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2004 | 369 | 0.050 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2002 | 3 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2002 | 28 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2002 | 97 | 0.050 |
Why?
|
| Renal Insufficiency | 1 | 2002 | 57 | 0.040 |
Why?
|
| Fetus | 1 | 2002 | 86 | 0.040 |
Why?
|
| Pain, Postoperative | 1 | 2004 | 193 | 0.040 |
Why?
|
| North Carolina | 1 | 2016 | 1550 | 0.040 |
Why?
|
| Pre-Eclampsia | 1 | 2002 | 66 | 0.040 |
Why?
|
| Hypercapnia | 1 | 2000 | 5 | 0.040 |
Why?
|
| Acidosis | 1 | 2000 | 18 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2000 | 69 | 0.040 |
Why?
|
| Carbon Dioxide | 1 | 2000 | 39 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 622 | 0.040 |
Why?
|
| Evidence-Based Practice | 1 | 2020 | 28 | 0.040 |
Why?
|
| Apgar Score | 1 | 2000 | 8 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2000 | 11 | 0.040 |
Why?
|
| Oxygen | 1 | 2000 | 144 | 0.040 |
Why?
|
| Double-Blind Method | 3 | 2009 | 543 | 0.040 |
Why?
|
| Infection Control | 1 | 2018 | 29 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2019 | 75 | 0.040 |
Why?
|
| Parity | 1 | 1998 | 19 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2000 | 240 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2018 | 120 | 0.030 |
Why?
|
| Stereoisomerism | 1 | 1997 | 20 | 0.030 |
Why?
|
| Pulse | 1 | 1997 | 10 | 0.030 |
Why?
|
| Cerebral Ventricles | 1 | 1997 | 12 | 0.030 |
Why?
|
| Neural Inhibition | 1 | 1997 | 27 | 0.030 |
Why?
|
| Animals | 2 | 2000 | 7599 | 0.030 |
Why?
|
| Naloxone | 1 | 1997 | 29 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 188 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 566 | 0.030 |
Why?
|
| Self Administration | 1 | 1998 | 293 | 0.030 |
Why?
|
| Heart Rate | 1 | 1997 | 345 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 1469 | 0.030 |
Why?
|
| Aged | 1 | 2016 | 10637 | 0.020 |
Why?
|
| Heart Rate, Fetal | 1 | 2009 | 8 | 0.020 |
Why?
|
| Conscious Sedation | 1 | 2009 | 23 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 115 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2010 | 338 | 0.020 |
Why?
|
| Paresthesia | 1 | 2005 | 9 | 0.010 |
Why?
|
| Catheterization | 1 | 2005 | 57 | 0.010 |
Why?
|
| Injections, Epidural | 1 | 2004 | 9 | 0.010 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2004 | 5 | 0.010 |
Why?
|